However, tumor endocrine status (negative vs positive; HR 1.40; P = 0.017), race (Black vs White and Asian vs White; HR 3.71 and 1.38, respectively; P = 0.011), previous adjuvant/neoadjuvant chemotherapy/HER2-targeted therapy (yes vs no; HR 1.39; P = 0.016), and number of metastatic sites (2 vs 1, 3 vs 1, and ≥ 4 vs 1; HR 1.44, 1.51, and 2.46, respectively; P < 0.001) had an effect on OS. Here, ERBB2 is linked to neoplasm.